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Abstract 
Background: The 2017 WHO model list of essential medicines for children grouping of antibiotics 
(Access, Watch, Reserve: AWaRe) provides an opportunity to review and plan antibiotic access and 
stewardship at country level. 
Methods: Oral antibiotic formulations appropriate for use in young children (defined as child-
appropriate formulations, CAFs) were identified from IQVIA-MIDAS® wholesale data, and 2015 
antibiotic consumption was estimated for 70 countries with reference to the AWaRe groups. We 
evaluated Access antibiotic and amoxicillin sales as a percentage of total CAF sales (Access 
percentage and Amoxicillin-Index), and the Access/Watch ratio (Access/Watch-Index) at country-
level. 
Findings: The median Access percentage among 70 countries was 76·3% (IQR 62·6-84·2%), 
confirming the key role of this antibiotic group in treating young children globally. However, in a 
quarter of countries Watch antibiotics accounted for ≥20% of total consumption. The Amoxicillin-
Index was low (median 30·7%, IQR 14·3-47·3%). Finally, the median Access/Watch-Index was 6·0 
(IQR 3·1-9·8). CAF antibiotic consumption patterns were highly variable between the 70 countries, 
without a clear split between high-income and middle-income countries. 
Interpretation: A simple combination of metrics based on the AWaRe groups can be informative on 
individual countries’ pattern of antibiotic consumption and stewardship opportunities. These metrics 
may support countries in developing programmes to improve access to core Access antibiotics, 
particularly amoxicillin. 
Funding: Global Antibiotic R&D Partnership with funding from German Federal Ministry of Health, 
Médecins Sans Frontières, Netherlands Ministry of Health, Welfare and Sport and UK Department for 
International Development. 
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Introduction 
Increasing rates of antimicrobial resistance are a threat to global child health. Child mortality due to 
pneumonia and sepsis are currently not predicted to achieve the Sustainable Development Goals.
1,2
 
Ensuring appropriate access to antibiotics while avoiding excess use, especially of unnecessarily 
broad-spectrum agents, is a major challenge in all settings, but particularly so in lower and middle 
income countries (LMICs).
3,4
 Around 90% of all antibiotics are used in the community, and this is 
potentially where the largest impact for antibiotic access and stewardship may be achieved.
5-7
 
However, the optimal approach to monitoring antibiotic use in the community remains unclear, 
especially when detailed data on indication are lacking.
8-10
 
Child-appropriate formulations (CAFs) can be defined as oral liquid formulations and solid 
formulations that are primarily dissolved or dispersed or become liquid upon swallowing.
11
 In 
antibiotic sales or high-level aggregate dispensing data, the volume of CAFs is likely to be directly 
linked to antibiotic drug use among young children, mostly those below 5 years of age, who find 
swallowing solid formulations challenging.
12-15
 Manipulation, such as crushing, of formulations 
suitable for adults is not recommended due to increased dosing variability and issues around 
stability.
16
 Inpatient children and neonates treated with antibiotics receive parenteral treatment in 79% 
and 98% of cases, respectively.
17
 Given that hospital consumption of antibiotics accounts for 10% or 
less of the total and in the light of low use of oral medications among inpatients, utilization of CAFs 
can be assumed to be broadly representative of community antibiotic use in this age group.  
The 2017 revision of the model list of essential medicines for children (EMLc) attempts to mirror the 
pressure on healthcare systems and clinicians to conserve antibiotics by classifying antibiotics into 
three groups.
18
 Access antibiotics are to be used first or second line for key infections, and high-quality 
formulations of these should be widely available at low cost. Watch antibiotics are considered to have 
a higher potential for selecting antibiotic resistance. Finally, Reserve antibiotics should be considered 
antibiotics of last resort to be used under specialist guidance and with specific monitoring. The explicit 
recommendation is that this new categorisation should also be used to inform antibiotic stewardship, at 
a national and global level.
19
 
A comprehensive list of common infection syndromes was generated and included in the 2017 EMLc. 
For each of these syndromes, recommended first and second line antibiotics were defined and included 
in the Access list. Currently, the EMLc list includes 17 Core Access antibiotics and 9 Watch 
antibiotics that are classified as Access only for defined indications (Access-Watch).
19,20
 In a 
stewardship context, countries may be able to enhance the use of Access antibiotics without impacting 
on overall access to adequate antibiotic treatment. In children, who are most frequently treated with 
antibiotics for respiratory tract infections, amoxicillin as the recommended first line treatment option 
would be expected to dominate the Access antibiotic prescribing as well as overall antibiotic use. 
We aimed to review the current levels of use of CAF for antibiotics, globally. To do this, we 
summarized 2015 wholesale data on antibiotics sold as CAFs to generate in-depth information on 
country-specific patterns by describing, amongst all CAFs sold, the percentage of Access group use, 
amoxicillin use (Amoxicillin-Index), and the relative use of Access and Watch antibiotics 
(Access/Watch-Index). 
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Methods 
We used data from the IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS®) 
database to describe global patterns of antibiotic utilization in young children. The IQVIA-MIDAS® 
is a commercial database, which contains annual pharmacy retail sales data collected throughout the 
supply chain. In essence, these data include information on the overall volume of antibiotics sold to 
retail and hospital pharmacies by wholesalers. Importantly, no information is available on individual 
prescriptions (indication or age of treated patient).
21
  
As not all wholesalers contribute in the represented countries, adjustments are made to estimate the 
likely total sales volume based on knowledge of the market share of participating wholesalers.
21
 The 
exact data collection mechanism and method of adjustment for variable country-level coverage are not 
publicly available, which limits an assessment of likely data representativeness. Consequently, 
between-country comparisons should be made with caution.
4
 However, IQVIA-MIDAS® and its 
predecessors have been used for evaluations of global antibiotic consumption patterns.
4,22
 Previous 
analyses were able to document high coverage of at least 80% in most countries, with particularly 
strong representation of the retail sector. Current information on coverage was not available.
22
  
Data on antibiotic sales (defined as products with an associated Anatomic Therapeutic Chemical code 
J01) from 70 countries for 2015 were considered. Guatemala, El Salvador, Honduras, Nicaragua, 
Costa Rica and Panama are reported aggregated as Central America in the IQVIA-MIDAS® database. 
The same is true for Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Democratic Republic of the 
Congo, Gabon, Guinea, Mali, Senegal and Togo as French West Africa. These regions were not 
included in our analyses. No country-level data for low-income countries are included in IQVIA-
MIDAS®. Therefore only data from high-income and middle-income countries as defined by the 
World Bank are shown.  
Antibiotic consumption was estimated based on the sales volume reported in standard units. Each 
standard unit is defined by IQVIA-MIDAS® as a single tablet, capsule, ampoule, vial or 5 millilitres 
of a liquid preparation for oral consumption.
23
 To identify antibiotics likely to have been prescribed 
and dispensed to young children, we classified all recorded oral antibiotic formulations as either child-
appropriate and specifically designed for easy use in children or not. CAFs were identified by two 
senior paediatric specialist pharmacists and independently by two of the authors (YH and JB) 
(Supplement 1). Parenteral antibiotic formulations were not considered as it is generally not possible 
to identify vials/ampoules for use in children.  
Patterns of antibiotic consumption were described in reference to the 2017 WHO EMLc Access, 
Watch, Reserve (AWaRe) grouping. Since the EMLc AWaRe grouping of antibiotics excludes some 
antibiotics, we also included an “Unclassified” group in addition to the Access, Watch and Reserve 
groups. This group includes (i) antibiotics belonging to a class represented in the EMLc by only one or 
two specific agents (e.g. narrow-spectrum penicillins: phenoxymethylpenicillin is the only member of 
this group on the EMLc); (ii) antibiotic classes not represented in the EMLc (e.g. second generation 
cephalosporins), (iii) fixed combinations of antibiotics excluding beta-lactam/beta-lactam inhibitor 
combinations and trimethoprim/sulfamethoxazole (regardless of whether any or all components are 
included in the EMLc).  
Only the Core Access antibiotics were considered part of the Access group.
20
 We included Access-
Watch antibiotics in the Watch group, as most oral Access-Watch antibiotics are to be used as first 
choice in a limited number of indications (azithromycin – cholera, ciprofloxacin – dysentery, low-risk 
febrile neutropenia, pyelonephritis).  
 5 
Three simple metrics to allow for assessment of intra-country patterns and to help identify broad areas 
of antibiotic use that would most likely benefit from stewardship efforts were considered. 
(1) We determined the percentage of use of Access, Watch, Reserve and Unclassified antibiotics 
for each of the represented countries (Access percentage and AWaRe distribution). This was 
calculated for each country as the number of CAF standard units of antibiotics in each 
group/total number of CAF standard units. 
(2) We then determined the Amoxicillin-Index (Amox-I). This was calculated as previously 
described as the number of amoxicillin CAF standard units/total number of CAF standard 
units.
10
  
(3) Finally we calculated the relative use of Access to Watch antibiotics expressed as the ratio of 
Access to Watch CAF standard units (Access/Watch-Index, AW-I). 
The Access percentage and AW-I patterns were described relative to the rounded median of the 70 
countries for which data were available. Based on published data suggesting a high percentage of total 
antibiotic prescribing to young children being accounted for by amoxicillin (see Research in Context), 
the Amox-I was described relative to the rounded upper quartile.  
Role of the funding source 
The funder had no influence on data analysis or interpretation, writing of the manuscript or on the 
decision to submit for publication. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
Results 
Overall, the median volume of CAF antibiotic standard units sold in 2015 per country was 74·5 
million (IQR 12·4-210·7 million). The country with the lowest volume of CAF standard units was 
Luxembourg (1·7 million) and the countries with the highest volume were India (4175·4 million), 
China (2406·7 million) and Pakistan (1472·6 million).  
Percentage use by AWaRe group  
There was substantial variation in the percentage of CAF antibiotic use accounted for by Access and 
Watch groups between the 70 countries (Figure 1). Access group use ranged from 94·4% of total use 
in Slovenia to 27·0% in Bangladesh, with a median of 76·3% (IQR 62·6-84·2%). For the Watch 
group, percentage use was highest in Japan (54·0%) and lowest in Slovenia (3·3%). The median 
percentage of Watch antibiotic use was 12·3% (IQR 8·8-19·8%). Reserve group use of 1% or more 
was only observed in Egypt (1%). In some countries, a considerable percentage of CAF antibiotics 
were not AWaRe classified (median 9·7%, IQR 4·7-15·5%), ranging from 0·8% in Russia to 33·6% in 
Germany. 
Access/Watch-Index 
The median AW-I was 6·0 (IQR 3·1-9·8), interpretable as 6 standard units of CAF Access antibiotics 
being consumed for each unit of Watch antibiotics. The lowest AW-I was seen in Bangladesh (0·5) 
and the highest in Slovenia (28·6). In general, the highest AW-I was observed in countries with the 
highest proportional use of Access antibiotics, however, some countries with a high percentage of 
Unclassified use had high AW-I despite comparatively low Access percentages (e.g. Luxembourg: 
AW-I 7·3, Access percentage 74·4%, Unclassified percentage 15·4% and Egypt: AW-I 7·0, Access 
percentage 62·6%, Unclassified percentage 27·4%; Figure 2).  
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There were six countries with an AW-I below one (Bangladesh, China, India, Japan, Kuwait, 
Vietnam), meaning that less than one standard unit of Access antibiotics was consumed for each 
standard unit of Watch antibiotics in those countries.  
There were 27 countries with both Access percentage and AW-I above the respective medians (Figure 
S1). The remaining 43 countries either had an Access percentage below the median (≤75%) or an AW-
I below the median (≤6). Nine countries (Croatia, Czech Republic, France, Malaysia, Russia, Serbia, 
Sri Lanka, Tunisia) had an Access percentage >75% but an AW-I ≤6. In these countries most of the 
non-Access group CAF antibiotics were from the Watch group. Only seven countries (Austria, Egypt, 
Ireland, Luxembourg, Poland, Romania and the UK) had an Access percentage ≤75% but an AW-I >6. 
In these countries a high percentage of Unclassified use of at least 15% was observed. 
Amoxicillin-Index  
Amoxicillin use as a percentage of all CAFs was highly variable (median Amox-I 30·7%, IQR 14·3-
47·3%), and was highest in Belgium (69·8%) and lowest in Kuwait (0·1%) (Figure 3).  
There were 11 countries with an Amox-I below 10% (Austria, Czech Republic, Egypt, Hungary, India, 
Kuwait, Saudi Arabia, Slovakia, South Korea, Turkey, Ukraine), indicating that less than 10% of CAF 
antibiotic use was for amoxicillin.  
There were only 13 countries with an Access percentage>75% and with an Amox-I >50% (Argentina, 
Belgium, Canada, Colombia, France, Lithuania, New Zealand, Peru, Slovenia, South Africa, Thailand, 
USA and Uruguay; Figure S2). Of note, two of these countries had an AW-I ≤6 (France 4·0, Thailand 
5·8). In total, 29 countries had an Access percentage above the median and an Amox-I in the upper 
quartile. Most of these countries (23/29) also had an AW-I >6.  
The total sales volume of CAF standard units, percentage use of Access, Watch, Reserve and EMLc 
unclassified antibiotic CAFs as well as the Amox-I and AW-I for all countries are listed in Supplement 
2 (Tables S1 and S2).  
Discussion 
Using the IQVIA-MIDAS® database, we first defined and identified child-appropriate oral antibiotic 
formulations and then assessed their global use against the new 2017 EMLc AWaRe classification. 
Our analysis confirms the key role of Access antibiotics for young children worldwide. Median 
percentage of Access antibiotic use was above 76%, and the first quartile was 63% or greater. 
Therefore only 17 of 70 evaluated countries used less than 63% Access antibiotics. Furthermore, we 
were able to verify that Access antibiotics are widely used not only in middle-income countries but 
also in high-income countries. Concerningly, the median percentage of Watch antibiotic use was 12% 
or more. The third quartile was nearly 20%, meaning that in 17 of 70 countries Watch antibiotic use 
exceeded 20%. A high level of Watch group use was generally reflected in a low ratio of Access to 
Watch use, the AW-I. Amoxicillin use, as measured by the Amox-I, was variable with amoxicillin 
generally accounting for a small fraction of overall prescribing.  
As expected, patterns of CAF antibiotic use were found to be highly variable across 70 countries. The 
three countries with the highest percentage use of Access antibiotics were Slovenia and the 
Netherlands (high-income), and Brazil (middle-income). Similarly, the three countries with the lowest 
Access percentage were Japan (high-income), and Bangladesh and China (middle-income). In line 
with data from hospital antibiotic use, China and India, the two most populous countries, were among 
the countries with the lowest Access percentage (27·0% and 35·0%), the highest Watch percentage 
(54·0% and 47·3%) and considerable use of unclassified antibiotics (18·9% and 17·4%).
24,25
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AWaRe unclassified antibiotics, including most fixed combinations of antibiotics, have been identified 
as being of particular interest for informing stewardship efforts.
26
 The Unclassified group may 
contribute to either narrower-spectrum (beta-lactamase resistant penicillins) or broader-spectrum 
(second generation cephalosporins) antibiotic use. The exact direction will be determined by country-
specific consumption patterns of Unclassified group antibiotics. The limitations of the AWaRe 
classification in this respect have previously been noted, and further guidance is needed on how 
unclassified antibiotics can be incorporated into the classification to facilitate stewardship efforts.
20
 
We were able to confirm that utilization of AWaRe unclassified antibiotics was as high as 33·6% 
(Germany), and in 25 countries exceeded the use of Watch antibiotics. In these countries, relative 
utilization of CAF antibiotic groups can be difficult to interpret because reclassification of antibiotics 
under the AWaRe approach could result in relevant shifts in Access or Watch percentages and AW-I. 
Three aspects of community antibiotics use in young children are striking: First, young children have 
been identified as the highest users of antibiotics, and use has been repeatedly shown to be much 
higher among younger than among older children.
27-34
 This provides some justification for focusing on 
CAFs given that establishing patterns of antibiotic utilization for the youngest age group would be 
expected to have the largest impact for antibiotic stewardship and antibiotic access.
2
 
Second, at least two-thirds and up to 90% of outpatient antibiotic prescriptions in young children are 
for respiratory tract infections (RTIs).
28,35-45
 These include upper RTIs, mainly otitis media and 
pharyngitis, in which antibiotic treatment may not necessarily be required in many cases. Equally, 
when antibiotics are prescribed, most international guidance suggests that narrow-spectrum options 
such as amoxicillin or phenoxymethylpenicillin should be used.
19,46-49
 Of note, data from the 
ambulatory sector in some LMIC settings suggest that RTIs are a less dominant indication for 
antibiotic use than in most high-income countries, with undifferentiated fever being a more frequent 
reason for an antibiotic prescription.
37,50-52
 The high use of antibiotics for patients with febrile illness in 
regions with endemic malaria even when rapid malaria diagnostics are available has recently been 
noted.
53
  
Third and directly related to the importance of RTIs as an indication for community antibiotic 
prescribing in young children, a limited number of specific antibiotics, all of them Access antibiotics, 
dominate utilization patterns in children. Amoxicillin alone accounts for up to 70% of overall 
community antibiotic use among young children in the Netherlands.
10,43,54
 Very high levels of 
amoxicillin use making up 50% or more of all prescriptions have also been described for Canada, 
France, Madagascar, Nigeria, Norway, Senegal, the US and the UK among children up to 5 years of 
age.
10,27,28,37,42,55,56
 In the US in 2010, amoxicillin was the drug most frequently prescribed to children 
in the outpatient setting and accounted for more than 18 million prescriptions.
31
 In Germany and the 
UK narrow-spectrum oral penicillins, such as phenoxymethylpenicillin, make up more than 10% of 
community antibiotic prescribing, and in Denmark these account for over a third of all prescriptions in 
this age group.
10,29,39,57
 In contrast, low amoxicillin use, often below 10%, has been observed in 
Greece, Italy and South Korea.
27,36,58
 In these countries, other Access antibiotics, for example co-
amoxicillin, may be used preferentially.  
Our analysis has several caveats. IQVIA-MIDAS® provides estimates based on proprietary 
algorithms. For these reasons, IQVIA-MIDAS® data are known to potentially result in under- or 
overestimation of antibiotic sales, and this effect may differ by country. Furthermore, extrapolation 
from antibiotic sales to antibiotic consumption may lead to overestimation of the latter if not all 
standard units sold are taken by the child.  
 8 
Similarly, this analysis based on standard units is unusual. The adoption of antibiotic dose units as a 
measure of antibiotic utilization may be simple to implement and generate easily interpretable data, 
especially in pediatrics where Defined Daily Doses (DDD) are not easily applicable.
59
 An advantage 
of reporting antibiotic use in this way would be that a conversion into DDD would be possible from 
the combined information on dispensed packs, pack-sizes and standard units.  
However, reporting in standard units can be problematic when dosing regimens and treatment 
durations are highly variable between countries and between indications Analyses would be biased 
towards higher Access group use, for example, if Access antibiotics are consistently administered for 
longer periods or dosed more frequently than Watch antibiotics. Moderate acuity infections treated 
with oral antibiotics are unlikely to require prolonged treatment or high-frequency dosing regimens.  
We attempted to limit our analysis to formulations that would be suitable for administration to young 
children. The classification of CAFs was based on expert opinion and may need further evaluation. 
Furthermore, non-CAFs may be used for the treatment of older children or when CAFs are not 
available, and CAFs may on occasion be used in other patient groups, such as elderly patients or those 
with a neurological disability. Many liquid formulations and dispersible tablets have a strength that 
renders them unsuitable for adult dosing, therefore reducing the likelihood of these formulations being 
used in other patient groups. 
While the Access percentage and AW-I may be transferable to analyses considering non-CAFs, it is 
unclear whether the Amox-I is likely to be as relevant to assessing antibiotic consumption patterns in 
adults as it is in young children. Some data on antibiotic use amongst children and adults, however, 
suggest that antibiotic prescriptions for RTIs are as common among adult patients in the community as 
for children.
33,60-62
  
Because of the difficulties in determining which children may be using CAFs in each country and 
because of the likely influence of antibiotic dosing regimens and durations, we did not standardise 
antibiotic use according to population as has previously been done in international comparisons.
22
 As 
the focus of our analysis was the identification of broad areas for stewardship intervention at the 
national level, we primarily evaluated the relative use of different antibiotics under the AWaRe 
grouping.  
Although the proportional use of antibiotics according to AWaRe, the AW-I and the Amox-I have the 
benefits of being informative, intuitive and simple to calculate, they too have specific limitations. 
Countries with a high percentage of use of Unclassified antibiotics may consider reclassification of 
these drugs into the AWaRe groups, for example based on relatedness to currently listed antibiotics. 
However, they can already use the AW-I to evaluate the general tendency towards greater use of 
broader-spectrum drugs. The Amox-I begins to address the challenge that the AWaRe grouping does 
not directly provide information on the spectrum of antibiotics.
20
 For example, amoxicillin/clavulanic 
acid is classified as an Access antibiotic but has been considered broad-spectrum in a quality indicator 
developed for assessment of community antibiotic use in Europe.
63
 However, the Amox-I fails to 
reflect high levels of use of even more narrow-spectrum agents, such as observed in some 
Scandinavian countries. 
This is, to our knowledge, the first attempt at developing simple metrics of global child community 
antibiotic use based on the WHO AWaRe classification. We were able to show considerable global 
variation in the utilization of CAF Access and Watch antibiotics. Interpreting Access percentage, AW-
I and Amox-I together can help to identify targets for national antibiotic stewardship efforts, 
particularly when the percentage of AWaRe unclassified antibiotics is low. In the first instance, 
countries with low Access percentages could identify opportunities for greater use of these antibiotics 
 9 
for community-based treatment of young children. Countries with moderate or high Access 
percentages but low Amox-I may prefer to focus on promoting the use of amoxicillin especially for 
RTIs, as recommended in the AWaRe guidance. A low AW-I may indicate unnecessary use of Watch 
antibiotics, which could again be specifically targeted. Challenges remain in settings with high 
percentages of Unclassified antibiotic use, which may need to be reduced or integrated into the 
AWaRe classification, depending on exact patterns.  
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Research in context 
Evidence before this study: There is limited reported data on patterns of community antibiotic use 
among children, and much of it is focused on specific databases in high-income countries. We carried 
out a systematic review of the literature on Medline® (search strategy (antibacterial OR antibiotic) 
AND (drug utilization OR practice patterns) AND (date limit 2010 to current) without age or language 
limitations; search last carried out on Feb, 4
th
 2018) to identify reports of antibiotic prescribing 
patterns in paediatric ambulatory care. Studies of antibiotic prescribing only in specific indications, 
such as community-acquired pneumonia, were excluded. In total, we identified 24 relevant 
publications from high-income country settings (Canada, Denmark, France, Germany, Greece, Ireland, 
Italy, Latvia, Netherlands, Norway, Serbia, Spain, South Korea, United Kingdom, United States) and 
only 6 from lower or middle income countries (Bangladesh, Brazil, Indonesia, Madagascar, Nigeria, 
Senegal and pooled data from Gambia, Ghana, Kenya, Nigeria and Uganda). No unifying approach in 
presenting prescribing patterns could be identified across these studies, making studies difficult to 
compare. Published data confirm, however, that antibiotic use is highest, and generally at least double 
that of older children, in children up to 5 years of age. When reported, respiratory tract infections, 
including otitis media and pharyngitis, accounted for more than 60% of antibiotic prescriptions for 
young children. In line with this, in a number of studies very high levels of amoxicillin use of 50% or 
more in children up to 5 years of age were identified. 
Added value of this study: We first defined child-appropriate oral formulations (CAFs) and then 
analysed wholesale pharmacy data from a global database to describe global patterns of antibiotic use 
among young children at country level. We describe the relative use of CAF antibiotics by AWaRe 
group, including the ratio of Access to Watch group use (Access/Watch-Index) and the percentage of 
total prescribing accounted for by amoxicillin (Amoxicillin-Index). Joint interpretation of the three 
metrics will help to identify broad areas for national antibiotic stewardship and guideline development, 
even when information on indication is not available. Importantly, all three metrics should be 
interpreted together to obtain a rounded picture of national patterns of antibiotic use. A first analysis of 
global patterns of CAF antibiotic use demonstrates that (i) very high Access percentages can be 
observed among both high and middle income countries, (ii) the percentage of use of antibiotics 
unclassified under the grouping can be considerable and may be a challenge for interpreting patterns, 
and (iii) the percentage of use accounted for by amoxicillin is highly variable even among countries 
with high Access percentage.  
Implications of all the available evidence: High Access percentages are achieved across countries with 
highly variable healthcare systems and income classification. Reviewing national Access percentages 
and aiming to promote Access antibiotic use could be the first step for states wishing to engage in 
national antibiotic stewardship. Use of Unclassified antibiotics should be reviewed and reduced, or 
reclassification into the AWaRe groups considered at national level. The AW-I can be used to ensure 
that the use of Watch relative to Access antibiotics is minimised, and is especially useful when there is 
residual utilization of Unclassified antibiotics. For children, countries should strongly promote the use 
of amoxicillin for most common antibiotic treatment indications encountered in community practice.  
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Figure captions 
Figure 1: Percentage antibiotic use of child-appropriate oral formulations according to WHO AWaRe 
(Access Watch Reserve) group.  
Note that only Core Access antibiotics have been included in the Access group.  
Figure 2: Country-level Access/Watch-Index and Access percentage (percentage of CAF standard 
units of antibiotic used accounted for by Access antibiotics) grouped by high-income and middle-
income countries 
The two vertical lines indicate the rounded AW-I median (6) and the rounded median Access 
percentage (75%).  
Figure 3: Country-level amoxicillin and Access percentages grouped by high-income and middle-
income countries. 
The amoxicillin percentage (percentage of CAF standard units of antibiotic used accounted for by 
amoxicillin) corresponds to the Amoxicillin-Index. 
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Abstract 
Background: The 2017 WHO model list of essential medicines for children grouping of antibiotics 
(Access, Watch, Reserve: AWaRe) provides an opportunity to review and plan antibiotic access and 
stewardship at country level. 
Methods: Oral antibiotic formulations appropriate for use in young children (defined as child-
appropriate formulations, CAFs) were identified from IQVIA-MIDAS® wholesale data, and 2015 
antibiotic consumption was estimated for 70 countries with reference to the AWaRe groups. We 
evaluated Access antibiotic and amoxicillin sales as a percentage of total CAF sales (Access 
percentage and Amoxicillin-Index), and the Access/Watch ratio (Access/Watch-Index) at country-
level. 
Findings: The median Access percentage among 70 countries was 76·3% (IQR 62·6-84·2%), 
confirming the key role of this antibiotic group in treating young children globally. However, in a 
quarter of countries Watch antibiotics accounted for ≥20% of total consumption. The Amoxicillin-
Index was low (median 30·7%, IQR 14·3-47·3%). Finally, the median Access/Watch-Index was 6·0 
(IQR 3·1-9·8). CAF antibiotic consumption patterns were highly variable between the 70 countries, 
without a clear split between high-income and middle-income countries. 
Interpretation: A simple combination of metrics based on the AWaRe groups can be informative on 
individual countries’ pattern of antibiotic consumption and stewardship opportunities. These metrics 
may support countries in developing programmes to improve access to core Access antibiotics, 
particularly amoxicillin. 
Funding: Global Antibiotic R&D Partnership with funding from German Federal Ministry of Health, 
Médecins Sans Frontières, Netherlands Ministry of Health, Welfare and Sport and UK Department for 
International Development. 
 
 
 
  
 3 
Introduction 
Increasing rates of antimicrobial resistance are a threat to global child health. Child mortality due to 
pneumonia and sepsis are currently not predicted to achieve the Sustainable Development Goals.
1,2
 
Ensuring appropriate access to antibiotics while avoiding excess use, especially of unnecessarily 
broad-spectrum agents, is a major challenge in all settings, but particularly so in lower and middle 
income countries (LMICs).
3,4
 Around 90% of all antibiotics are used in the community, and this is 
potentially where the largest impact for antibiotic access and stewardship may be achieved.
5-7
 
However, the optimal approach to monitoring antibiotic use in the community remains unclear, 
especially when detailed data on indication are lacking.
8-10
 
Child-appropriate formulations (CAFs) can be defined as oral liquid formulations and solid 
formulations that are primarily dissolved or dispersed or become liquid upon swallowing.
11
 In 
antibiotic sales or high-level aggregate dispensing data, the volume of CAFs is likely to be directly 
linked to antibiotic drug use among young children, mostly those below 5 years of age, who find 
swallowing solid formulations challenging.
12-15
 Manipulation, such as crushing, of formulations 
suitable for adults is not recommended due to increased dosing variability and issues around 
stability.
16
 Inpatient children and neonates treated with antibiotics receive parenteral treatment in 79% 
and 98% of cases, respectively.
17
 Given that hospital consumption of antibiotics accounts for 10% or 
less of the total and in the light of low use of oral medications among inpatients, utilization of CAFs 
can be assumed to be broadly representative of community antibiotic use in this age group.  
The 2017 revision of the model list of essential medicines for children (EMLc) attempts to mirror the 
pressure on healthcare systems and clinicians to conserve antibiotics by classifying antibiotics into 
three groups.
18
 Access antibiotics are to be used first or second line for key infections, and high-quality 
formulations of these should be widely available at low cost. Watch antibiotics are considered to have 
a higher potential for selecting antibiotic resistance. Finally, Reserve antibiotics should be considered 
antibiotics of last resort to be used under specialist guidance and with specific monitoring. The explicit 
recommendation is that this new categorisation should also be used to inform antibiotic stewardship, at 
a national and global level.
19
 
A comprehensive list of common infection syndromes was generated and included in the 2017 EMLc. 
For each of these syndromes, recommended first and second line antibiotics were defined and included 
in the Access list. Currently, the EMLc list includes 17 Core Access antibiotics and 9 Watch 
antibiotics that are classified as Access only for defined indications (Access-Watch).
19,20
 In a 
stewardship context, countries may be able to enhance the use of Access antibiotics without impacting 
on overall access to adequate antibiotic treatment. In children, who are most frequently treated with 
antibiotics for respiratory tract infections, amoxicillin as the recommended first line treatment option 
would be expected to dominate the Access antibiotic prescribing as well as overall antibiotic use. 
We aimed to review the current levels of use of CAF for antibiotics, globally. To do this, we 
summarized 2015 wholesale data on antibiotics sold as CAFs to generate in-depth information on 
country-specific patterns by describing, amongst all CAFs sold, the percentage of Access group use, 
amoxicillin use (Amoxicillin-Index), and the relative use of Access and Watch antibiotics 
(Access/Watch-Index). 
 4 
Methods 
We used data from the IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS®) 
database to describe global patterns of antibiotic utilization in young children. The IQVIA-MIDAS® 
is a commercial database, which contains annual pharmacy retail sales data collected throughout the 
supply chain. In essence, these data include information on the overall volume of antibiotics sold to 
retail and hospital pharmacies by wholesalers. Importantly, no information is available on individual 
prescriptions (indication or age of treated patient).
21
  
As not all wholesalers contribute in the represented countries, adjustments are made to estimate the 
likely total sales volume based on knowledge of the market share of participating wholesalers.
21
 The 
exact data collection mechanism and method of adjustment for variable country-level coverage are not 
publicly available, which limits an assessment of likely data representativeness. Consequently, 
between-country comparisons should be made with caution.
4
 However, IQVIA-MIDAS® and its 
predecessors have been used for evaluations of global antibiotic consumption patterns.
4,22
 Previous 
analyses were able to document high coverage of at least 80% in most countries, with particularly 
strong representation of the retail sector. Current information on coverage was not available.
22
  
Data on antibiotic sales (defined as products with an associated Anatomic Therapeutic Chemical code 
J01) from 70 countries for 2015 were considered. Guatemala, El Salvador, Honduras, Nicaragua, 
Costa Rica and Panama are reported aggregated as Central America in the IQVIA-MIDAS® database. 
The same is true for Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Democratic Republic of the 
Congo, Gabon, Guinea, Mali, Senegal and Togo as French West Africa. These regions were not 
included in our analyses. No country-level data for low-income countries are included in IQVIA-
MIDAS®. Therefore only data from high-income and middle-income countries as defined by the 
World Bank are shown.  
Antibiotic consumption was estimated based on the sales volume reported in standard units. Each 
standard unit is defined by IQVIA-MIDAS® as a single tablet, capsule, ampoule, vial or 5 millilitres 
of a liquid preparation for oral consumption.
23
 To identify antibiotics likely to have been prescribed 
and dispensed to young children, we classified all recorded oral antibiotic formulations as either child-
appropriate and specifically designed for easy use in children or not. CAFs were identified by two 
senior paediatric specialist pharmacists and independently by two of the authors (YH and JB) 
(Supplement 1). Parenteral antibiotic formulations were not considered as it is generally not possible 
to identify vials/ampoules for use in children.  
Patterns of antibiotic consumption were described in reference to the 2017 WHO EMLc Access, 
Watch, Reserve (AWaRe) grouping. Since the EMLc AWaRe grouping of antibiotics excludes some 
antibiotics, we also included an “Unclassified” group in addition to the Access, Watch and Reserve 
groups. This group includes (i) antibiotics belonging to a class represented in the EMLc by only one or 
two specific agents (e.g. narrow-spectrum penicillins: phenoxymethylpenicillin is the only member of 
this group on the EMLc); (ii) antibiotic classes not represented in the EMLc (e.g. second generation 
cephalosporins), (iii) fixed combinations of antibiotics excluding beta-lactam/beta-lactam inhibitor 
combinations and trimethoprim/sulfamethoxazole (regardless of whether any or all components are 
included in the EMLc).  
Only the Core Access antibiotics were considered part of the Access group.
20
 We included Access-
Watch antibiotics in the Watch group, as most oral Access-Watch antibiotics are to be used as first 
choice in a limited number of indications (azithromycin – cholera, ciprofloxacin – dysentery, low-risk 
febrile neutropenia, pyelonephritis).  
 5 
Three simple metrics to allow for assessment of intra-country patterns and to help identify broad areas 
of antibiotic use that would most likely benefit from stewardship efforts were considered. 
(1) We determined the percentage of use of Access, Watch, Reserve and Unclassified antibiotics 
for each of the represented countries (Access percentage and AWaRe distribution). This was 
calculated for each country as the number of CAF standard units of antibiotics in each 
group/total number of CAF standard units. 
(2) We then determined the Amoxicillin-Index (Amox-I). This was calculated as previously 
described as the number of amoxicillin CAF standard units/total number of CAF standard 
units.
10
  
(3) Finally we calculated the relative use of Access to Watch antibiotics expressed as the ratio of 
Access to Watch CAF standard units (Access/Watch-Index, AW-I). 
The Access percentage and AW-I patterns were described relative to the rounded median of the 70 
countries for which data were available. Based on published data suggesting a high percentage of total 
antibiotic prescribing to young children being accounted for by amoxicillin (see Research in Context), 
the Amox-I was described relative to the rounded upper quartile.  
Role of the funding source 
The funder had no influence on data analysis or interpretation, writing of the manuscript or on the 
decision to submit for publication. The corresponding author had full access to all the data in the 
study and had final responsibility for the decision to submit for publication. 
Results 
Overall, the median volume of CAF antibiotic standard units sold in 2015 per country was 74·5 
million (IQR 12·4-210·7 million). The country with the lowest volume of CAF standard units was 
Luxembourg (1·7 million) and the countries with the highest volume were India (4175·4 million), 
China (2406·7 million) and Pakistan (1472·6 million).  
Percentage use by AWaRe group  
There was substantial variation in the percentage of CAF antibiotic use accounted for by Access and 
Watch groups between the 70 countries (Figure 1). Access group use ranged from 94·4% of total use 
in Slovenia to 27·0% in Bangladesh, with a median of 76·3% (IQR 62·6-84·2%). For the Watch 
group, percentage use was highest in Japan (54·0%) and lowest in Slovenia (3·3%). The median 
percentage of Watch antibiotic use was 12·3% (IQR 8·8-19·8%). Reserve group use of 1% or more 
was only observed in Egypt (1%). In some countries, a considerable percentage of CAF antibiotics 
were not AWaRe classified (median 9·7%, IQR 4·7-15·5%), ranging from 0·8% in Russia to 33·6% in 
Germany. 
Access/Watch-Index 
The median AW-I was 6·0 (IQR 3·1-9·8), interpretable as 6 standard units of CAF Access antibiotics 
being consumed for each unit of Watch antibiotics. The lowest AW-I was seen in Bangladesh (0·5) 
and the highest in Slovenia (28·6). In general, the highest AW-I was observed in countries with the 
highest proportional use of Access antibiotics, however, some countries with a high percentage of 
Unclassified use had high AW-I despite comparatively low Access percentages (e.g. Luxembourg: 
AW-I 7·3, Access percentage 74·4%, Unclassified percentage 15·4% and Egypt: AW-I 7·0, Access 
percentage 62·6%, Unclassified percentage 27·4%; Figure 2).  
 6 
There were six countries with an AW-I below one (Bangladesh, China, India, Japan, Kuwait, 
Vietnam), meaning that less than one standard unit of Access antibiotics was consumed for each 
standard unit of Watch antibiotics in those countries.  
There were 27 countries with both Access percentage and AW-I above the respective medians (Figure 
S1). The remaining 43 countries either had an Access percentage below the median (≤75%) or an AW-
I below the median (≤6). Nine countries (Croatia, Czech Republic, France, Malaysia, Russia, Serbia, 
Sri Lanka, Tunisia) had an Access percentage >75% but an AW-I ≤6. In these countries most of the 
non-Access group CAF antibiotics were from the Watch group. Only seven countries (Austria, Egypt, 
Ireland, Luxembourg, Poland, Romania and the UK) had an Access percentage ≤75% but an AW-I >6. 
In these countries a high percentage of Unclassified use of at least 15% was observed. 
Amoxicillin-Index  
Amoxicillin use as a percentage of all CAFs was highly variable (median Amox-I 30·7%, IQR 14·3-
47·3%), and was highest in Belgium (69·8%) and lowest in Kuwait (0·1%) (Figure 3).  
There were 11 countries with an Amox-I below 10% (Austria, Czech Republic, Egypt, Hungary, India, 
Kuwait, Saudi Arabia, Slovakia, South Korea, Turkey, Ukraine), indicating that less than 10% of CAF 
antibiotic use was for amoxicillin.  
There were only 13 countries with an Access percentage>75% and with an Amox-I >50% (Argentina, 
Belgium, Canada, Colombia, France, Lithuania, New Zealand, Peru, Slovenia, South Africa, Thailand, 
USA and Uruguay; Figure S2). Of note, two of these countries had an AW-I ≤6 (France 4·0, Thailand 
5·8). In total, 29 countries had an Access percentage above the median and an Amox-I in the upper 
quartile. Most of these countries (23/29) also had an AW-I >6.  
The total sales volume of CAF standard units, percentage use of Access, Watch, Reserve and EMLc 
unclassified antibiotic CAFs as well as the Amox-I and AW-I for all countries are listed in Supplement 
2 (Tables S1 and S2).  
Discussion 
Using the IQVIA-MIDAS® database, we first defined and identified child-appropriate oral antibiotic 
formulations and then assessed their global use against the new 2017 EMLc AWaRe classification. 
Our analysis confirms the key role of Access antibiotics for young children worldwide. Median 
percentage of Access antibiotic use was above 76%, and the first quartile was 63% or greater. 
Therefore only 17 of 70 evaluated countries used less than 63% Access antibiotics. Furthermore, we 
were able to verify that Access antibiotics are widely used not only in middle-income countries but 
also in high-income countries. Concerningly, the median percentage of Watch antibiotic use was 12% 
or more. The third quartile was nearly 20%, meaning that in 17 of 70 countries Watch antibiotic use 
exceeded 20%. A high level of Watch group use was generally reflected in a low ratio of Access to 
Watch use, the AW-I. Amoxicillin use, as measured by the Amox-I, was variable with amoxicillin 
generally accounting for a small fraction of overall prescribing.  
As expected, patterns of CAF antibiotic use were found to be highly variable across 70 countries. The 
three countries with the highest percentage use of Access antibiotics were Slovenia and the 
Netherlands (high-income), and Brazil (middle-income). Similarly, the three countries with the lowest 
Access percentage were Japan (high-income), and Bangladesh and China (middle-income). In line 
with data from hospital antibiotic use, China and India, the two most populous countries, were among 
the countries with the lowest Access percentage (27·0% and 35·0%), the highest Watch percentage 
(54·0% and 47·3%) and considerable use of unclassified antibiotics (18·9% and 17·4%).
24,25
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AWaRe unclassified antibiotics, including most fixed combinations of antibiotics, have been identified 
as being of particular interest for informing stewardship efforts.
26
 The Unclassified group may 
contribute to either narrower-spectrum (beta-lactamase resistant penicillins) or broader-spectrum 
(second generation cephalosporins) antibiotic use. The exact direction will be determined by country-
specific consumption patterns of Unclassified group antibiotics. The limitations of the AWaRe 
classification in this respect have previously been noted, and further guidance is needed on how 
unclassified antibiotics can be incorporated into the classification to facilitate stewardship efforts.
20
 
We were able to confirm that utilization of AWaRe unclassified antibiotics was as high as 33·6% 
(Germany), and in 25 countries exceeded the use of Watch antibiotics. In these countries, relative 
utilization of CAF antibiotic groups can be difficult to interpret because reclassification of antibiotics 
under the AWaRe approach could result in relevant shifts in Access or Watch percentages and AW-I. 
Three aspects of community antibiotics use in young children are striking: First, young children have 
been identified as the highest users of antibiotics, and use has been repeatedly shown to be much 
higher among younger than among older children.
27-34
 This provides some justification for focusing on 
CAFs given that establishing patterns of antibiotic utilization for the youngest age group would be 
expected to have the largest impact for antibiotic stewardship and antibiotic access.
2
 
Second, at least two-thirds and up to 90% of outpatient antibiotic prescriptions in young children are 
for respiratory tract infections (RTIs).
28,35-45
 These include upper RTIs, mainly otitis media and 
pharyngitis, in which antibiotic treatment may not necessarily be required in many cases. Equally, 
when antibiotics are prescribed, most international guidance suggests that narrow-spectrum options 
such as amoxicillin or phenoxymethylpenicillin should be used.
19,46-49
 Of note, data from the 
ambulatory sector in some LMIC settings suggest that RTIs are a less dominant indication for 
antibiotic use than in most high-income countries, with undifferentiated fever being a more frequent 
reason for an antibiotic prescription.
37,50-52
 The high use of antibiotics for patients with febrile illness in 
regions with endemic malaria even when rapid malaria diagnostics are available has recently been 
noted.
53
  
Third and directly related to the importance of RTIs as an indication for community antibiotic 
prescribing in young children, a limited number of specific antibiotics, all of them Access antibiotics, 
dominate utilization patterns in children. Amoxicillin alone accounts for up to 70% of overall 
community antibiotic use among young children in the Netherlands.
10,43,54
 Very high levels of 
amoxicillin use making up 50% or more of all prescriptions have also been described for Canada, 
France, Madagascar, Nigeria, Norway, Senegal, the US and the UK among children up to 5 years of 
age.
10,27,28,37,42,55,56
 In the US in 2010, amoxicillin was the drug most frequently prescribed to children 
in the outpatient setting and accounted for more than 18 million prescriptions.
31
 In Germany and the 
UK narrow-spectrum oral penicillins, such as phenoxymethylpenicillin, make up more than 10% of 
community antibiotic prescribing, and in Denmark these account for over a third of all prescriptions in 
this age group.
10,29,39,57
 In contrast, low amoxicillin use, often below 10%, has been observed in 
Greece, Italy and South Korea.
27,36,58
 In these countries, other Access antibiotics, for example co-
amoxicillin, may be used preferentially.  
Our analysis has several caveats. IQVIA-MIDAS® provides estimates based on proprietary 
algorithms. For these reasons, IQVIA-MIDAS® data are known to potentially result in under- or 
overestimation of antibiotic sales, and this effect may differ by country. Furthermore, extrapolation 
from antibiotic sales to antibiotic consumption may lead to overestimation of the latter if not all 
standard units sold are taken by the child.  
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Similarly, this analysis based on standard units is unusual. The adoption of antibiotic dose units as a 
measure of antibiotic utilization may be simple to implement and generate easily interpretable data, 
especially in pediatrics where Defined Daily Doses (DDD) are not easily applicable.
59
 An advantage 
of reporting antibiotic use in this way would be that a conversion into DDD would be possible from 
the combined information on dispensed packs, pack-sizes and standard units.  
However, reporting in standard units can be problematic when dosing regimens and treatment 
durations are highly variable between countries and between indications Analyses would be biased 
towards higher Access group use, for example, if Access antibiotics are consistently administered for 
longer periods or dosed more frequently than Watch antibiotics. Moderate acuity infections treated 
with oral antibiotics are unlikely to require prolonged treatment or high-frequency dosing regimens.  
We attempted to limit our analysis to formulations that would be suitable for administration to young 
children. The classification of CAFs was based on expert opinion and may need further evaluation. 
Furthermore, non-CAFs may be used for the treatment of older children or when CAFs are not 
available, and CAFs may on occasion be used in other patient groups, such as elderly patients or those 
with a neurological disability. Many liquid formulations and dispersible tablets have a strength that 
renders them unsuitable for adult dosing, therefore reducing the likelihood of these formulations being 
used in other patient groups. 
While the Access percentage and AW-I may be transferable to analyses considering non-CAFs, it is 
unclear whether the Amox-I is likely to be as relevant to assessing antibiotic consumption patterns in 
adults as it is in young children. Some data on antibiotic use amongst children and adults, however, 
suggest that antibiotic prescriptions for RTIs are as common among adult patients in the community as 
for children.
33,60-62
  
Because of the difficulties in determining which children may be using CAFs in each country and 
because of the likely influence of antibiotic dosing regimens and durations, we did not standardise 
antibiotic use according to population as has previously been done in international comparisons.
22
 As 
the focus of our analysis was the identification of broad areas for stewardship intervention at the 
national level, we primarily evaluated the relative use of different antibiotics under the AWaRe 
grouping.  
Although the proportional use of antibiotics according to AWaRe, the AW-I and the Amox-I have the 
benefits of being informative, intuitive and simple to calculate, they too have specific limitations. 
Countries with a high percentage of use of Unclassified antibiotics may consider reclassification of 
these drugs into the AWaRe groups, for example based on relatedness to currently listed antibiotics. 
However, they can already use the AW-I to evaluate the general tendency towards greater use of 
broader-spectrum drugs. The Amox-I begins to address the challenge that the AWaRe grouping does 
not directly provide information on the spectrum of antibiotics.
20
 For example, amoxicillin/clavulanic 
acid is classified as an Access antibiotic but has been considered broad-spectrum in a quality indicator 
developed for assessment of community antibiotic use in Europe.
63
 However, the Amox-I fails to 
reflect high levels of use of even more narrow-spectrum agents, such as observed in some 
Scandinavian countries. 
This is, to our knowledge, the first attempt at developing simple metrics of global child community 
antibiotic use based on the WHO AWaRe classification. We were able to show considerable global 
variation in the utilization of CAF Access and Watch antibiotics. Interpreting Access percentage, AW-
I and Amox-I together can help to identify targets for national antibiotic stewardship efforts, 
particularly when the percentage of AWaRe unclassified antibiotics is low. In the first instance, 
countries with low Access percentages could identify opportunities for greater use of these antibiotics 
 9 
for community-based treatment of young children. Countries with moderate or high Access 
percentages but low Amox-I may prefer to focus on promoting the use of amoxicillin especially for 
RTIs, as recommended in the AWaRe guidance. A low AW-I may indicate unnecessary use of Watch 
antibiotics, which could again be specifically targeted. Challenges remain in settings with high 
percentages of Unclassified antibiotic use, which may need to be reduced or integrated into the 
AWaRe classification, depending on exact patterns.  
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Research in context 
Evidence before this study: There is limited reported data on patterns of community antibiotic use 
among children, and much of it is focused on specific databases in high-income countries. We carried 
out a systematic review of the literature on Medline® (search strategy (antibacterial OR antibiotic) 
AND (drug utilization OR practice patterns) AND (date limit 2010 to current) without age or language 
limitations; search last carried out on Feb, 4
th
 2018) to identify reports of antibiotic prescribing 
patterns in paediatric ambulatory care. Studies of antibiotic prescribing only in specific indications, 
such as community-acquired pneumonia, were excluded. In total, we identified 24 relevant 
publications from high-income country settings (Canada, Denmark, France, Germany, Greece, Ireland, 
Italy, Latvia, Netherlands, Norway, Serbia, Spain, South Korea, United Kingdom, United States) and 
only 6 from lower or middle income countries (Bangladesh, Brazil, Indonesia, Madagascar, Nigeria, 
Senegal and pooled data from Gambia, Ghana, Kenya, Nigeria and Uganda). No unifying approach in 
presenting prescribing patterns could be identified across these studies, making studies difficult to 
compare. Published data confirm, however, that antibiotic use is highest, and generally at least double 
that of older children, in children up to 5 years of age. When reported, respiratory tract infections, 
including otitis media and pharyngitis, accounted for more than 60% of antibiotic prescriptions for 
young children. In line with this, in a number of studies very high levels of amoxicillin use of 50% or 
more in children up to 5 years of age were identified. 
Added value of this study: We first defined child-appropriate oral formulations (CAFs) and then 
analysed wholesale pharmacy data from a global database to describe global patterns of antibiotic use 
among young children at country level. We describe the relative use of CAF antibiotics by AWaRe 
group, including the ratio of Access to Watch group use (Access/Watch-Index) and the percentage of 
total prescribing accounted for by amoxicillin (Amoxicillin-Index). Joint interpretation of the three 
metrics will help to identify broad areas for national antibiotic stewardship and guideline development, 
even when information on indication is not available. Importantly, all three metrics should be 
interpreted together to obtain a rounded picture of national patterns of antibiotic use. A first analysis of 
global patterns of CAF antibiotic use demonstrates that (i) very high Access percentages can be 
observed among both high and middle income countries, (ii) the percentage of use of antibiotics 
unclassified under the grouping can be considerable and may be a challenge for interpreting patterns, 
and (iii) the percentage of use accounted for by amoxicillin is highly variable even among countries 
with high Access percentage.  
Implications of all the available evidence: High Access percentages are achieved across countries with 
highly variable healthcare systems and income classification. Reviewing national Access percentages 
and aiming to promote Access antibiotic use could be the first step for states wishing to engage in 
national antibiotic stewardship. Use of Unclassified antibiotics should be reviewed and reduced, or 
reclassification into the AWaRe groups considered at national level. The AW-I can be used to ensure 
that the use of Watch relative to Access antibiotics is minimised, and is especially useful when there is 
residual utilization of Unclassified antibiotics. For children, countries should strongly promote the use 
of amoxicillin for most common antibiotic treatment indications encountered in community practice.  
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Figure captions 
Figure 1: Percentage antibiotic use of child-appropriate oral formulations according to WHO AWaRe 
(Access Watch Reserve) group.  
Note that only Core Access antibiotics have been included in the Access group.  
Figure 2: Country-level Access/Watch-Index and Access percentage (percentage of CAF standard 
units of antibiotic used accounted for by Access antibiotics) grouped by high-income and middle-
income countries 
The two vertical lines indicate the rounded AW-I median (6) and the rounded median Access 
percentage (75%).  
Figure 3: Country-level amoxicillin and Access percentages grouped by high-income and middle-
income countries. 
The amoxicillin percentage (percentage of CAF standard units of antibiotic used accounted for by 
amoxicillin) corresponds to the Amoxicillin-Index. 
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Web-extra material 
Table 1: List of oral formulations considered child-appropriate 
 Formulation IMS-MIDAS shorthand 
S
o
li
d
 
Oral Solid Ordinary Orally Disintegrating Tablets AAB (OR DISINTG TAB) 
Oral Solid Ordinary Buccal Tablets AAE (BUCCAL TABLETS) 
Oral Solid Ordinary Chewable Tablets AAG (CHEW.TABLETS) 
Oral Solid Ordinary Effervescent Tablets AAH (EFFERV.TABLETS) 
Oral Solid Ordinary Soluble Tablets AAK (SOLUBLE TABS.) 
Oral Solid Ordinary Powders AEA (POWDER ORAL) 
Oral Solid Ordinary Granules AEB (ORAL GRANULES) 
Oral Solid Ordinary Unit Dose Powders AEP (U-DOSE POWDERS) 
Oral Solid Retard Unit Dose Powders BEP (RET DOSE PWDR) 
Oral Solid Retard Other Powders/Granules BEY (OTH PDR/GRN RT) 
L
iq
u
id
 
Oral Liquid Unit Dose Pressurised Aerosols DEH (EFFERV PDR/GRN) 
Oral Liquid Ordinary Soluble Powders DEK (SOLUBLE POWDER) 
Oral Liquid Ordinary Unit Dose Powders DEP (ORAL U-D PWDR) 
Oral Liquid Ordinary Other Powders/Granules DEY (OTHER PDR/GRN) 
Oral Liquid Ordinary Liquids DGA (ORAL LIQUID) 
Oral Liquid Ordinary Drops DGB (DROPS ORAL) 
Oral Liquid Ordinary Dry Suspensions/Syrups/Drops DGJ (DRY SYRUP/DROP) 
Oral Liquid Ordinary Suspensions DGK (SUSPENSION) 
Oral Liquid Ordinary Syrups DGM (SYRUP) 
Oral Liquid Ordinary Unit Dose Liquids DGN (ORAL U-D LIQ) 
Oral Liquid Retard Soluble Powders EEK (RET SOLUB PDR.) 
Oral Liquid Retard Unit Dose Powders EEP (RET U-D PWDR) 
Table 2: Percentage use of antibiotics expressed as % of total child-appropriate formulation standard 
units recorded in IMS country-level wholesale data in 2015 for high-income countries 
Country SU sold (million) Access %* Watch %* Reserve %* Unclassified %* Amoxicillin % AW-I 
Australia 85.7 84.3 8.8 0.003 6.9 44.6 9.5 
Austria 16.5 72.6 11.5 0.01 15.8 8.1 6.3 
Belgium 46.8 87.6 8.9 0.01 3.5 69.8 9.9 
Canada 95.1 85.9 8.5 0.006 5.6 66.5 10.1 
Chile 30.7 73.1 12.3 0.0 14.6 53.0 5.6 
Czech Republic 12.4 75.8 15.4 0.0 8.8 4.5 4.9 
Estonia 1.6 65.5 17.9 0.0 16.6 34.9 3.7 
Finland 5.5 83.3 4.7 0.0 12.1 37.2 17.8 
France 467.4 78.7 19.7 0.008 1.6 54.4 4.0 
Germany 121.9 46.8 19.6 0.03 33.6 24.6 2.4 
Greece 67.7 69.0 12.2 0.0 18.8 30.2 5.7 
Hungary 17.5 62.6 19.5 0.0 17.9 6.9 3.2 
Ireland 23.0 71.4 11.0 0.07 17.5 33.8 6.5 
Italy 241.4 68.2 27.7 0.008 4.0 22.3 2.5 
Japan 255.1 34.4 51.0 0.0 14.6 27.0 0.7 
Kuwait 6.4 43.6 49.4 0.0 7.0 0.1 0.9 
Latvia 3.2 77.6 12.3 0.0 10.0 46.3 6.3 
Lithuania 7.3 78.1 11.3 0.0 10.6 60.1 6.9 
Luxembourg 1.6 74.4 10.2 0.0 15.4 50.1 7.2 
Netherlands 39.4 92.3 3.4 0.0 4.3 42.5 27.2 
New Zealand 28.6 81.0 6.8 0.002 12.2 50.7 11.9 
Norway 5.4 85.3 10.0 0.0 4.7 19.7 8.5 
Poland 115.3 72.5 12.0 0.0 15.5 21.0 6.1 
Portugal 29.9 84.2 6.8 0.004 9.0 29.9 12.3 
Puerto Rico 9.9 82.8 10.5 0.005 6.7 41.3 7.9 
Saudi Arabia 150.8 56.0 33.0 0.0 11.0 7.8 1.7 
Singapore 7.3 72.5 23.7 0.04 3.8 14.3 3.1 
Slovakia 12.1 49.5 26.9 0.0 23.6 1.9 1.8 
Slovenia 6.1 94.4 3.3 0.0 2.3 53.1 28.9 
South Korea 238.4 58.0 29.5 0.0 12.5 0.6 2.0 
Spain 213.2 90.4 7.4 0.02 2.2 48.0 12.3 
Sweden 8.8 81.9 3.9 0.0 14.2 13.7 21.0 
Switzerland 11.8 87.1 9.3 0.01 3.6 34.3 9.4 
UK 197.1 73.2 12.1 0.05 14.7 42.5 6.1 
Uruguay 7.5 85.8 5.0 0.0 9.1 68.9 17.0 
USA 1185.0 86.7 11.9 0.1 1.4 54.5 7.3 
*rounding errors may result in the total of Access+Watch+Reserve+Unclassified coming to slightly more or less 
than 100% 
Necessary additional data
Click here to download Necessary additional data: Web_material_IMS_analysis_17July2018.docx
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Table 3: Percentage use of antibiotics expressed as % of total child-appropriate formulation standard 
units recorded in IMS country-level wholesale data in 2015 for middle-income countries  
Country SU sold (million) Access %* Watch %* Reserve %* Unclassified %* Amoxicillin % AW-I 
Algeria 583.7 90.2 8.2 0.0 1.6 46.6 11.0 
Argentina 124.5 87.4 8.7 0.0 4.0 55.1 10.1 
Bangladesh 498.5 29.0 44.4 0.1 26.4 16.5 0.7 
Bosnia 7.4 80.8 4.6 0.0 14.6 15.3 17.5 
Brazil 499.5 90.5 4.4 0.0 5.1 47.2 20.5 
Bulgaria 23.8 62.5 25.6 0.0 11.8 25.2 2.4 
China 2406.6 27.0 54.0 0.0 18.9 10.7 0.5 
Colombia 85.3 89.6 4.0 0.0 6.3 59.5 22.1 
Croatia 11.7 76.7 15.1 0.0 8.2 23.4 5.1 
Dominican 
Republic  
7.8 67.4 16.6 0.0 16.0 35.6 4.1 
Ecuador 71.8 77.5 6.3 0.0 16.2 31.1 12.3 
Egypt 648.6 62.6 9.0 1.0 27.4 7.6 6.9 
India 4175.3 35.0 47.3 0.2 17.4 9.6 0.7 
Indonesia 247.9 71.6 12.9 0.0 15.5 48.3 5.6 
Jordan 25.8 68.0 27.3 0.0 4.7 11.6 2.5 
Kazakhstan 50.1 84.6 12.6 0.0 2.9 27.7 6.7 
Lebanon 20.9 57.2 34.7 0.0 8.2 11.2 1.6 
Malaysia 92.5 77.3 17.4 0.004 5.4 33.9 4.4 
Mexico 143.4 69.8 18.1 0.0 12.1 11.7 3.9 
Morocco 210.1 89.5 4.1 0.0 6.3 39.8 21.6 
Pakistan 1472.6 57.6 24.8 0.05 17.6 19.2 2.3 
Peru 80.0 83.5 7.2 0.0 9.3 69.7 11.6 
Philippines 165.3 72.6 16.8 0.0002 10.5 29.2 4.3 
Romania 77.1 69.5 11.2 0.0 19.3 14.8 6.2 
Russia 297.6 79.4 19.8 0.002 0.8 44.9 4.0 
Serbia 32.0 83.9 14.1 0.0 2.0 44.4 6.0 
South Africa 226.9 85.4 12.2 0.004 2.4 50.4 7.0 
Sri Lanka 38.3 80.5 13.9 0.0 5.6 19.1 5.8 
Thailand 126.9 78.8 12.1 0.0 9.1 51.4 6.5 
Tunisia 113.3 84.0 14.3 0.0 1.7 47.3 5.9 
Turkey 776.5 56.6 28.1 0.0001 15.3 2.6 2.1 
Ukraine 46.7 61.9 34.2 0.0 3.9 0.4 1.8 
Venezuela 103.3 55.9 15.6 0.0 28.5 14.7 3.6 
Vietnam 210.6 37.1 43.1 0.0 19.8 11.6 0.9 
 
*rounding errors may result in the total of Access+Watch+Reserve+Unclassified coming to slightly more or less 
than 100% 
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Figure S1: Scatterplot of 
Access percentage and 
Access/Watch-Index.  
 
Dark blue dots: 
countries with Access 
percentage and AW-I 
above the rounded 
median (indicated by 
dashed lines, Access 
percentage 75%, AW-I 
6). Orange dots: Access 
percentage or AW-I or 
both equal to or below 
median. Dotted line 
indicates AW-I of 1 
where Access use 
equals Watch use. For 
countries below the 
dotted line more Watch 
standard units are sold 
than Access standard 
units. 
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Figure S2: Scatterplot of 
Access percentage and 
Amoxicillin-Index.  
Dark blue dots: 
Countries with an AW-I 
above the median of 6. 
Light blue dots: 
Countries with an AW-I 
equal to or below the 
median. The dashed 
lines indicate the 
rounded median Access 
percentage (75%) and 
Amox-I (30%), the 
dotted line indicates the 
rounded upper Amox-I 
quartile (50%). 
